| skip sub-navigation, go to content.
|
|
Rapid Access to Preventive Intervention Development (RAPID) Program
|
Supported Investigators
Projects Initiated in:
FY 2009 |
FY 2008 |
FY 2007 |
FY 2006 |
FY 2005 |
FY 2004 |
FY 2003 |
FY 2002 |
FY 2001
FY 2000
Expand All | Close All
Projects Initiated in FY 2009
 |
Principal Investigator
& Institute |
Title of Project |
Prevention Agent
Under Study |
Chinthalapally V. Rao, Ph.D.
Oklahoma University |
Development of phospho-ibuprofen for pancreatic cancer prevention |
Phospho-ibuprofen |
|
Program Description
Phospho-ibuprofen is covalently modified form of ibuprofen aimed to decrease adverse effects and increase potency of ibuprofen. Preliminary data demonstrated pancreatic chemopreventive effects of phosphor-ibuprofen in vitro and in vivo. The initial RAPID support may include:
- Scale-up manufacture for preclinical studies and
- Preclinical toxicological and pharmacological testing
Contact Information
Chinthalapally V. Rao, Ph.D.
Professor of Medicine
Oklahoma University Cancer Institute
Biomedical Research Building, Room 1203,
OU Health Sciences Center
Oklahoma City, OK 73
Tel: 405-271-3224
Fax: 405-271-3225
close
|
 Back to Top
Projects Initiated in FY 2008
No awards were made in FY 2008
Projects Initiated in FY 2007
|
Principal Investigator
& Institute |
Title of Project |
Prevention Agent
Under Study |
Lenard M. Lichtenberger, Ph.D.
The University of Texas |
Development of Purified Ibuprofen-PC for Colon Cancer Prevention |
Ibuprofen-phosphatidylcholine complex |
|
Program Description
Ibuprofen-PC, a non-covalently associated ibuprofen-phosphatidylcholine (PC) complex, may obviate gastro-intestinal toxicities (bleeding and ulceration) of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) as well as cardiovascular toxicity of selective COX-2 NSAIDs. Preliminary studies have shown ibuprofen-PC to have greater efficacy than ibuprofen or aspirin in cell culture and animal colon cancer models. The initial RAPID support may include:
- Scale-up production method for highly purified ibuprofen-PC
Contact Information
Lenard M. Lichtenberger, Ph.D.
Professor of Integrative Biology and Pharmacology
The University of Texas Health Science Center at Houston
Mailing address: Dept. of Integrative Biology and Pharmacology
The University of Texas Medical School
6431 Fannin
Houston, TX 77030-1503
Telephone: 713-500-6320
Fax: 713-500-7444
close
|
|
Hirak S. Basu, Ph.D.
University of Wisconsin |
A Novel Prostate Directed Anti-Oxidant (Polyamine Oxidase Inhibitor) for Prostate Cancer Prevention |
Polyamine oxidase inhibitor, MDL72,527 |
|
Program Description
Polyamine oxidase inhibitor MDL72,527 was shown to completely abrogate androgen induced oxidative stress in androgen dependent human prostate cancer cells and markedly reduce oxidative stress in the prostate gland and significantly delay prostate tumor development and prolong the overall survival of the TRansgenic Adenocarcinoma in Mouse Prostate (TRAMP) mice. The initial RAPID support may include:
- Scale-up manufacture for preclinical studies and
- Preclinical toxicological and pharmacological testing
Contact Information
Hirak S. Basu, Ph.D.
University of Wisconsin
Paul P. Carbone Comprehensive Cancer Center
K6/522 CSC, 600 Highland Avenue
Madison WI 53792-5669
Phone: (608) 265-4912
Fax: (608) 265-8133
close |
|
Doris M. Benbrook, Ph.D.
University of Oklahoma HSC |
Flex-Het Chemoprevention |
Flexible heteroarotinoid, SHetA2 |
|
Program Description
Synthetic Flexible Heteroarotinoid (Flex-Het) compounds, even though originally modeled after retinoids, function independently of the retinoid receptors and toxicities. SHetA2 along with other Flex-Hets were shown to induce differentiation and inhibit tumor growth and angiogenesis without evidence of toxicity. The initial RAPID support may include:
- Scale-up manufacture for preclinical studies and
- Preclinical toxicological and pharmacological testing
Contact Information
Doris M. Benbrook, Ph.D.
University of Oklahoma HSC
Department of OB/GYN
PO BOX 26901, Room WP 2470
Oklahoma City OK, 73190
Phone: (405) 271-5523
FAX: (405) 271-2976
close
|
Back to Top
Projects Initiated in FY 2006
|
Principal Investigator
& Institute |
Title of Project |
Prevention Agent
Under Study |
Glenn Liu, M.D.
University of Wisconsin |
Pentamethylchromanol as a Novel Chemopreventive Antiandrogen and Antioxidant to Prevent Prostate Cancer Progression |
Pentamethylchromanol |
|
Program Description
2, 2, 5, 7 ,8-pentamethyl-6-chromanol (PMCol) combines two mechanisms of action, anti-androgenic and antioxidant, which have a potential utility for prevention of prostate cancer as shown in preliminary preclinical studies. The initial RAPID support may include:
- cGMP manufacture for preclinical studies and
- Preclinical toxicological and pharmacological testing.
Contact Information
Glenn Liu, M.D.
University of Wisconsin
Madison, WI
Tel: (608) 265-8689
Fax: (608) 265-8133
close
|
|
Richard Roden, Ph.D.
Johns Hopkins University |
Production of a Minor Capsid Protein L2 11-200 Vaccine with Adjuvant for the Prevention of HPV-Associated Disease |
Capsid Protein L2 11-200 HPV Vaccine |
|
Program Description
Unlike vaccination with L1 VP, vaccination with HPV L2 induces antibodies that cross-neutralize diverse HPV genotypes, suggesting the possibility of a pan-HPV prophylactic vaccine derived from L2 sequences. The project details are under development.
Contact Information
Richard Roden, Ph.D.
Johns Hopkins University
Baltimore, MD
Tel: (410) 502-5161
Fax: (443) 287-4295
close
|
Back to Top
Projects Initiated in FY 2005
|
Principal Investigator
& Institute |
Title of Project |
Prevention Agent
Under Study |
Ming You, M.D., Ph.D.
Washington University School of Medicine |
Anti-tumor B (ATB), Chinese herbal mixture of six plants, for prevention of lung and upper aerodigestive tract tumors |
Anti-tumor B |
|
Program Description
ATB has exhibited chemopreventive activity in animal models of lung cancer and in previous clinical studies in smokers with bronchial or esophageal dysplasia. The initial RAPID support may include:
- Development of standardized ATB mixture for use in preclinical and clinical studies
- Preclinical toxicological and pharmacological testing
- Isolation, identification, and characterization of key components.
Contact Information
Ming You, M.D., Ph.D.
Washington University School of Medicine
St. Louis, MO
Tel: (314) 362-9294
Fax: (314) 362-9366
close
|
Back to Top
Projects Initiated in FY 2004
|
Principal Investigator
& Institute |
Title of Project |
Prevention Agent
Under Study |
Michael B. Sporn, M.D.
Dartmouth Medical School |
Bulk synthesis of a new triterpenoid, ethyl 2-carboxy-3,12-dioxooleana-1,9(11)-dien-28-oate (NSC #D722320, TP-222) (concluded) |
Synthetic Triterpenoid |
|
Program Description
Several new synthetic triterpenoids have shown chemopreventive and chemotherapeutic activities including growth inhibition of leukemia and carcinoma cells, induction of tumor cell differentiation, and suppression of de novo synthesis of COX-2 and iNOS. TP-222 has been synthesized to overcome pharmacokinetic limitations of previous triterpenoids and has shown a promising in vivo activity. The RAPID support will include bulk synthesis of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) for further evaluation of chemopreventive activity.
Contact Information
Michael B. Sporn, M.D.
Dartmouth Medical School
Dartmouth, NH
Tel: 603-650-6557
Fax: 603-650-1129
View investigator's other projects
close
|
|
Russell F. Jacoby, M.D.
University of Wisconsin-Madison |
Polyamine analog SL11217 for prevention of colon and duodenal neoplasia |
Porphyrin Polyamine Conjugate |
|
Program Description
Experimental evidence suggests that regulating polyamine metabolism may be useful in the prevention and treatment of colon cancer. Polyamine analogs and polyamine synthesis inhibitors have shown chemopreventive activities. SL-11217, a novel porphyrin polyamine conjugate, yielded encouraging preliminary results. It combines the antiproliferative effects of polyamine analogs with tumor-targeting potential of porphyrins which are expected to maximize efficacy and minimize systemic toxicity. The initial RAPID support may include:
- Scale up GMP synthesis and
- Preclinical pharmacology and toxicology studies.
Contact Information
Russell F. Jacoby, M.D.
University of Wisconsin-Madison
Madison, WI
Tel: 608-256-1901
Fax: 608-280-7292
close
|
Back to Top
Expand All | Close All
Next page >
|
|
|
